Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

SLAMF7 in Primary Effusion Lymphoma, Target for Individualized Therapy?

Hilmar Quentmeier, PhD, Claudia Pommerenke, PhD, Wilhelm G Dirks, PhD, Vivien Hauer, Max Koeppel, PhD, Stefan Nagel, PhD, Michaela Scherr, PhD, Margarete Zaborski, Hans G. Drexler, MD PhD

Blood (2018) 132 (Supplement 1): 5300.

https://doi.org/10.1182/blood-2018-99-110054

Published: 2018

Journal Articles

FOXR1 Activation in B-Cell Lymphoma

Hilmar Quentmeier, PhD, Claudia Pommerenke, PhD, Stefan Nagel, PhD, Vivien Hauer, Margarete Zaborski, Rose Marie Amini, PhD, Mattias Berglund, PhD, Robert Geffers, PhD, Hans G Drexler, Prof. MD

Blood (2015) 126 (23): 2422.

https://doi.org/10.1182/blood.V126.23.2422.2422

Published: 2015

Journal Articles

Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells

Jie Ding, PhD, Julia Romani, Margarete Zaborski, Roderick AF MacLeod, PhD, Stefan Nagel, PhD, Hans G. Drexler, MD, PhD, Hilmar Quentmeier, PhD

Blood (2013) 122 (21): 4906.

https://doi.org/10.1182/blood.V122.21.4906.4906

Published: 2013

Journal Articles

Induction of Apoptosis In Imatinib-Resistant BCR-ABL1 -Positive Leukemia Cell Lines by Bortezomib

Hilmar Quentmeier, PhD, Sonja Eberth, PhD, Julia Romani, Margarete Zaborski, Hans G. Drexler, MD, PhD

Blood (2010) 116 (21): 4469.

https://doi.org/10.1182/blood.V116.21.4469.4469

Published: 2010

Journal Articles

CRLF2 and JAK2 Mutations: Occurrence and Function In Pre-B ALL Cell Lines

Hilmar Quentmeier, PhD, Sonja Eberth, PhD, Roderick AF MacLeod, PhD, Stefan Nagel, PhD, Julia Romani, Margarete Zaborski, Hans G. Drexler, MD, PhD

Blood (2010) 116 (21): 5109.

https://doi.org/10.1182/blood.V116.21.5109.5109

Published: 2010

Journal Articles

Hypermethylation of CD44 Is Characteristic of Specific Lymphoma Subtypes.

Sonja Röhrs, Julia Romani, Margarete Zaborski, Andreas Rosenwald, Hans G. Drexler, Hilmar Quentmeier

Blood (2009) 114 (22): 3469.

https://doi.org/10.1182/blood.V114.22.3469.3469

Published: 2009

Journal Articles

JAK2 V617F Tyrosine Kinase Mutation in Leukemia Cell Lines.

Hilmar Quentmeier, PhD, Roderick A.F. MacLeod, PhD, Julia Reinhardt, Margarete Zaborski, Hans G. Drexler, PhD

Blood (2005) 106 (11): 4505.

https://doi.org/10.1182/blood.V106.11.4505.4505

Published: 2005

NARROW

SLAMF7 in Primary Effusion Lymphoma, Target for Individualized Therapy?

FOXR1 Activation in B-Cell Lymphoma

Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells

Induction of Apoptosis In Imatinib-Resistant BCR-ABL1 -Positive Leukemia Cell Lines by Bortezomib

CRLF2 and JAK2 Mutations: Occurrence and Function In Pre-B ALL Cell Lines

Hypermethylation of CD44 Is Characteristic of Specific Lymphoma Subtypes.

JAK2 V617F Tyrosine Kinase Mutation in Leukemia Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

SLAMF7 in Primary Effusion Lymphoma, Target for Individualized Therapy?

FOXR1 Activation in B-Cell Lymphoma

Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells

Induction of Apoptosis In Imatinib-Resistant BCR-ABL1 -Positive Leukemia Cell Lines by Bortezomib

CRLF2 and JAK2 Mutations: Occurrence and Function In Pre-B ALL Cell Lines

Hypermethylation of CD44 Is Characteristic of Specific Lymphoma Subtypes.

JAK2 V617F Tyrosine Kinase Mutation in Leukemia Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only